investor harm

Ardent Health faces class action lawsuit for overstating Q3 2025 revenue and EBITDA guidance by $57.5 million due to inadequate accounting assessments and cost pressures.

Fermi Inc. faces securities class action over alleged false statements regarding Project Matador campus development and undisclosed single-tenant dependency risks.

BellRing Brands faces class action lawsuit alleging it misrepresented sales performance by failing to disclose that revenue growth was driven by customer inventory buildup rather than organic demand.

BellRing Brands faces class action lawsuit alleging it misrepresented sales growth as organic demand when it actually stemmed from customer inventory restocking following supply chain disruptions.

PayPal faces class action lawsuit alleging executives made false statements about revenue projections and 2027 financial targets, failing to disclose material risks to investors.

Kyndryl faces class action lawsuit alleging false financial statements and internal control weaknesses from August 2024 to February 2026, affecting investors who purchased securities during this period.

Class action lawsuit filed against Vistagen Therapeutics for alleged false statements regarding drug trial data. Investors who purchased securities April 2024-December 2025 may be eligible.

Enphase Energy faces class action lawsuit for allegedly misleading investors about inventory management and tax credit expiration impact during April-October 2025.

uniQure faces class action lawsuit alleging misleading statements about FDA study status and BLA timeline delays. Investors who purchased shares Sept-Oct 2025 may be eligible to claim.

PomDoctor faces class action lawsuit alleging fraudulent stock promotion scheme involving false statements, insider sales, and market manipulation between October-December 2025.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.

Class action lawsuit filed against Picard Medical for alleged securities fraud involving false statements, insider share sales, and social media misinformation to artificially inflate stock price.

Oracle faces a class action lawsuit alleging it failed to disclose financial risks tied to its AI infrastructure investments, citing misaligned capital spending and revenue growth.

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.

Class action lawsuit filed against Klarna over IPO disclosure claims, alleging risk reserves were materially understated in regulatory filings.

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities inflated stock prices. Investors who bought shares between February-October 2025 may qualify.

Class action lawsuit filed against NuScale Power for allegedly misrepresenting nuclear partner ENTRA1's experience. Investors claim material misstatements about partner's qualifications were not disclosed timely.

Class action lawsuit filed against agilon health for allegedly making false 2026 guidance claims and overstating financial benefits of risk-reduction initiatives, harming investors.

Ramaco Resources faces class action lawsuit for allegedly misleading investors about Brook Mine operations. Executives reportedly made false statements about the facility's status despite holding a public groundbreaking ceremony.

Masonite faces class action lawsuit alleging executives concealed acquisition offers while repurchasing stock at depressed prices. Investors who bought shares June 2023-February 2024 are eligible.